Skip to content

Anika Therapeutics ANIK Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Net margin-9.9%+36.6pp-46.5%+3.1pp-49.6%-40.1pp-9.5%
Returns
Return on equity-7.5%+23.3pp-30.8%+2.4pp-33.2%-28.0pp-5.2%
Efficiency
Asset turnover0.6×+0.1×0.5×0.0×0.5×+0.1×0.4×0.0×
Liquidity
Current ratio4.7×-0.2×4.9×-0.4×5.3×-0.8×6.1×+0.4×
Leverage
Debt-to-equity0.2×0.0×0.2×0.0×0.1×0.0×0.1×0.0×
Valuation
Market capitalization$204.37M+31.6%$241.07M-27.3%$331.76M-23.3%$432.45M-16.4%
Price / sales1.8×+0.1×0.0×-0.8×2.8×-0.7×
Price / book1.5×+0.5×1.6×0.0×1.6×0.0×1.5×-0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Anika Therapeutics's ratios come from?
Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.